研究生教育

浙江大学基础医学院药理系副教授，博士生导师。北京大学药学院本科及硕士，英国诺丁汉大学药学博士，MRC LMB/剑桥大学博士后，2020年入选“浙江大学基础研究长周期考核计划”。

研究与成果：

主要从事抗肿瘤药理、分子药剂学、细胞外基质及肿瘤微环境研究，特别是通过应用纳米药物递送策略调控肿瘤微环境细胞（成纤维细胞、巨噬细胞、树突状细胞等）用于耐药及转移肿瘤的治疗，以及免疫治疗。近五年来主持国家自然科学基金青年及面上项目3项，省基金1项，“以民促军”基础培育计划1项，横向项目3项。以通讯作者/共同通讯作者在Science Advances, Biomaterials, Journal of Controlled Release等期刊发表论文10篇，以第一发明人获得授权专利3项。DARU Journal of Pharmaceutical Sciences 编委，Science Advances, Advanced Functional Materials, Biomaterials, Theranostics, Journal of Controlled Release等期刊审稿人。

代表性论文：

• Nanoparticle-Enhanced Chemo-immunotherapy to Trigger Robust Antitumor Immunity. Science Advances 2020

• Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy. Science Advances 2020 accepted

• Autophagy-inhibiting polymer as an effective nonviral cancer gene therapy vector with inherent apoptosis-sensitizing ability. Biomaterials 2020

• New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. Journal of Controlled Release，2018

• Terminating the criminal collaboration in cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Biomaterials, 2017

招生信息：

预计每年招收药理学推免或申请考核博士生1名，生物与医药工程硕士1名，欢迎药学,分子/细胞生物学,化学等专业学生加入。